An observational study in Fabry Disease, sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Fabry Disease with a site in United States — 13 open to participants now, 18 under way, 6 of them phase 3. Fabry Disease · United States.
Among the 94 studies in Fabry Disease with a site in United States, this one is the 21st largest by planned enrollment of the 34 observational ones that give a count, is one of 5 that started in 2023, is one of 34 observational ones, reaches primary completion later than 0 of the 17 other live ones, and was the 87th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →13 of the 94 studies in Fabry Disease with a site in United States are open now. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States
Ages 18+
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
Chiesi Farmaceutici S.p.A. · Sites in United States, Austria, France and 3 more countries
Ages 2–17
Chiesi Farmaceutici S.p.A. · Sites in United States, Germany, Italy and 2 more countries
Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 23 · Phase 3 22 · Phase 4 7
First in 1995; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 100 across 122 observational studies indexed under Fabry Disease.
Median enrollment 22 across the 58 interventional studies, 54 across the 34 observational. Of the 66 that completed or were terminated, 37 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 94 have an industry lead sponsor. The 10 most frequent:
Lysosomal and Rare Disorders Research and Treatment Center, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Lysosomal and Rare Disorders Research and Treatment Center, Inc. has 2 studies filed under Fabry Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Fabry Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 94 studies in Fabry Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to collect biological samples (urine) to develop assays for immune biomarkers to possibly in the future be able to screen subjects with Fabry disease and be able to understand better progression of nephropathy in Fabry disease and predict nephropathy in Fabry disease.
This is a study to assess the markers related to autophagy, apoptosis, pyroptosis, and inflammatory markers related to NFkB, TNF-alpha, and TGF-β1 pathways in the urine. Urinary biomarkers will then be compared to the standard measures of kidney function and proteinuria: GFR, cystatin-C, B2M, bikunin, NGAL. Gb3 and Lyso-Gb3, urine microalbumin, and urine protein-to-creatinine (UPCR) ratio. Investigators will also analyze the role of therapy, especially for the inflammatory responses in participants on stable enzyme replacement therapy (ERT) with that of patients naïve to therapy.
There will be a total of 25 biomarkers that will be assessed during the study. Biomarkers of inflammation
There is no particular study population being investigated. Only patient with Fabry disease and healthy controls from across the world will be enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No deterioration of kidney function.
Deterioration of kidney function.
These patients have no received treatment.
Not diagnosed with Fabry disease.
identify urinary inflammatory biomarkers associated with nephropathy in Fabry disease, Units pg/ml
IL-1β, TNF-α, IL-6, Il-4, IL-8, Il-10, Il-12, Il-18, MCP1, RANTES, BAFF, APRIL, TGF-β1, INF-gamma, and PAI-1will be measured in urine.
Time frame: through study completion, an average of 2 years
Identify biomarkers of renal glomerular function, tubular injury and endothelial dysfunction. Units pg/ml
B2M, GFR, albumin, cystatin C, osteopontin, clusterin, creatinine, EGF, NGAL, KIM-1, alpha-1-microglobulin, bikunin, YKL-40, CK-18 M30.
Time frame: through study completion, an average of 2 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2023 (actual). Primary completion is estimated for Jul 2025, 21 months after the start.
Of 61 observational studies under Fabry Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 36. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lysosomal and Rare Disorders Research and Treatment Center, Inc.